What is CyteGen?
Founded in 2015 and headquartered in Wauwatosha, United States, CyteGen operates at the intersection of high-throughput biology and machine learning. The company has developed a sophisticated proprietary platform that integrates complex genomics, proteomics, and biochemical datasets. By leveraging artificial intelligence and advanced data analytics, CyteGen facilitates the discovery of novel biological pathways, effectively accelerating the research and development lifecycle for pharmaceutical and biotech partners. Its market position is defined by its ability to transform disparate biological signals into actionable insights, positioning the firm as a critical infrastructure provider in the modern drug discovery ecosystem.
How much funding has CyteGen raised?
CyteGen has raised a total of $1.1M across 1 funding round:
Other Financing Round
$1.1M
Other Financing Round (2022): $1.1M, investors not publicly disclosed
Key Investors in CyteGen
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for CyteGen?
With this major strategic investment, CyteGen is well-positioned to scale its computational capabilities and expand its research footprint. The company is expected to prioritize the enhancement of its AI-driven discovery engine, potentially targeting new therapeutic areas that require deep, multi-omic integration. As the firm transitions into a more mature enterprise-level phase, the focus will likely shift toward commercializing its discovery platform through strategic partnerships and expanding its internal pipeline of proprietary biological targets. This capital infusion provides the necessary runway to sustain long-term innovation and maintain a competitive edge in the rapidly evolving landscape of data-driven life sciences.
See full CyteGen company page
